4DMedical Expands Presence in U.S. Academic Health Systems
4DMedical Limited (ASX: 4DX) has secured a significant commercial arrangement with UC San Diego Health for the clinical use of its CT:VQ™ technology. This collaboration marks the fourth U.S. academic medical center to adopt the technology, following institutions like Stanford and Cleveland Clinic. CT:VQ™ offers a high-resolution, contrast-free alternative to traditional nuclear medicine VQ scans, providing functional lung imaging that improves diagnostic accuracy. The partnership with UCSD, one of the top U.S. institutions for pulmonology, further validates 4DMedical's commercialization strategy, building momentum for broader market adoption. With FDA clearance achieved just four months ago, the rapid integration of CT:VQ™ into prestigious medical centers underscores its transformative potential in pulmonary imaging. 4DMedical’s expanding portfolio, including partnerships with Philips and Imbio, strengthens its position as a leader in advancing respiratory care globally.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to this. Read our Privacy Policy and Terms & Conditions
4DMedical Expands Presence in U.S. Academic Health Systems
4DMedical Limited (ASX: 4DX) has secured a significant commercial arrangement with UC San Diego Health for the clinical use of its CT:VQ™ technology. This collaboration marks the fourth U.S. academic medical center to adopt the technology, following institutions like Stanford and Cleveland Clinic. CT:VQ™ offers a high-resolution, contrast-free alternative to traditional nuclear medicine VQ scans, providing functional lung imaging that improves diagnostic accuracy. The partnership with UCSD, one of the top U.S. institutions for pulmonology, further validates 4DMedical's commercialization strategy, building momentum for broader market adoption. With FDA clearance achieved just four months ago, the rapid integration of CT:VQ™ into prestigious medical centers underscores its transformative potential in pulmonary imaging. 4DMedical’s expanding portfolio, including partnerships with Philips and Imbio, strengthens its position as a leader in advancing respiratory care globally.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au